Accordingly, targeting Tregs via CD25-antibody (Daclizumab) or by a DTx-IL2-fusion protein (ONTAK) did not benefit melanoma patients due to effector cell elimination [58, 59]. This evidence concerns the gene IL2 and melanoma.